Months after promising help for “hundreds of thousands of kids,” the FDA approved the decades-old medicine for a disease documented in less than 50 people.
An examination of the technical and historical literature concerning the discovery and development of antibiotics suggests the possible existence of an era of discovery. This era appears to have a well-defined beginning (about 1940) and a well-defined close (about 1960). It is the purpose of this dissertation to examine the various strands of evidence that support the thesis that a definable antibiotic discovery era does indeed exist. An examination of several antibiotics discovered and developed during the period 1940-1960 support the thesis. One antibiotic in particular, vancomycin, discussed in depth is shown to be exemplary of the trends established about 1940 and which ceased to function about 1960. In concluding, a definition for the discovery era is proposed.
When it comes to conversations about vaccines and autism, we always have plenty to write about. And the latest news that the Trump administration has tapped David Geier for a study on possible links between immunizations and autism, first reported by the Washington Post, is no exception.
Starboard Value, the activist investor agitating for change at Pfizer, called on the pharmaceutical giant’s board of directors to hold the company’s executives responsible for what it described as a yearslong pattern of underperformance.
FDA held a Non-prescription Drug Advisory Committee meeting Sept. 11-12, 2023, to discuss the effectiveness of oral phenylephrine as an active ingredient in over-the-counter (OTC) cough and cold products.
Il 93% della popolazione cubana è coperta da una dose, l’87% ha completato la doppia somministrazione e ben il 97% della popolazione pediatrica dai due anni in su è vaccinata. Tutti con i vaccini sviluppati e prodotti a L’Avana. Tra quelli approvati e quelli in studio, i vaccini sotto indagine sono addirittura cinque. Che cosa ha reso possibile a un’isola caraibica con 11
Through high-stakes litigation, aggressive patenting practices and a bit of luck, Amgen will likely stretch Enbrel's monopoly until 2029, more than 30 years after it was approved.
